

24th May, 2024

The Dy. General Manager (Listing Dept.)
BSE Limited,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept., National Stock Exchange of India Ltd., Exchange Plaza, 5th Floor, Plot No. C/1, G. Block, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 051 (NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Presentation to analysts on Audited Financial Results for the quarter and year ended 31st March, 2024

The presentation on Audited Financial Results for the quarter and year ended 31st March, 2024 to be made to analysts is enclosed for your records.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED

CHINTAN M. TRIVEDI COMPANY SECRETARY

Encl: A/a



Q4 FY 2023-24

Revenues: Summary



Revenue: Summary

Revenues (Rs cr)	Q4 FY24	Q4 FY23	Gr%
India	1,380	1,257	10%
United States	262	280	-6%
Germany	280	253	11%
Brazil	372	318	17%
Others	451	384	17%
Total	2,745	2,491	10%



Revenue: Summary

Revenues (Rs cr)	FY24	FY23	Gr%
India	5,666	4,984	14%
United States	1,078	1,162	-7%
Germany	1,074	928	16%
Brazil	1,126	935	20%
Others	1,784	1,611	11%
Total	10,728	9,620	12%

